Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
CA 2243983 A1 · Owner: Centrapharm Inc. · Inventors: Bruttmann, Georges; Kerouac, Rene
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to sublingual drug formulations containing active ingredients in dosages equal to or near standard oral dosages. A portion of sublingual form is sublingually absorbed and the remaining portion of the same is absorbed mainly by the enteral route. These formulations have a more rapid onset of action than and a termination of action similar to that of oral forms. As a result the pharmacological, effect is prolonged (almost doubled). Overall total bioavailability is the same as for oral forms. Formulations useful in the treatment of allergy and asthma are disclosed. They comprise at least one of the following: a .beta.2-mimetic a corticosteroid, an anti-H1, histamine an …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 17, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 17, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 17, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.